SCHEMBL845294

SCHEMBL845294

CN1CC(Cl)=C(Cl)C1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3060656 0.65 CRBN (0.34)
SCHEMBL12748060 0.64
SCHEMBL407513 0.63 BLM (0.42)
SCHEMBL12384203 0.63
SCHEMBL18671722 0.61
SCHEMBL31319116 0.61 ALDH1A1 (0.36)
SCHEMBL31319117 0.61 ALDH1A1 (0.36)
SCHEMBL12305806 0.59
SCHEMBL10765843 0.59
SCHEMBL19721811 0.59 CRBN (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3915556-A1 RECTAL APPLICATION OF THALIDOMIDE IN PATIENTS WITH HEMORRHAGIC CHRONIC RADIATION PROCTITIS Vonnahme, Franz Josef (DE) 2021-12-01 EP disclosed
US-20120142734-A1 METHODS FOR TREATING TUMORS WITH THALIDOMIDE THE CHILDREN'S MEDICAL CENTER CORPORATION 2012-06-07 US disclosed
US-8143283-B1 Methods for treating blood-born tumors with thalidomide THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2012-03-27 US disclosed
US-7723361-B2 Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide CELGENE CORPORATION (US) 2010-05-25 US disclosed